InVivoPlus anti-mouse PD-1 (CD279)

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. Grasselly C et al., 2018, Front Immunol

Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Triplett TA et al., 2018 Sep, Nat Biotechnol

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Moynihan KD et al., 2016 Dec, Nat Med

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Zelenay S et al., 2015 Sep 10, Cell

A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. Ngiow SF et al., 2015 Sep 15, Cancer Res

PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity. Zander RA et al., 2015 May 13, Cell Host Microbe

TGFbeta Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Vanpouille-Box C et al., 2015 Jun 1, Cancer Res

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Twyman-Saint Victor C et al., 2015 Apr 16, Nature

Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Evans EE et al., 2015 Jun, Cancer Immunol Res

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Mittal D et al., 2014 Jul 15, Cancer Res